Galapagos NV

GLPG30 Nov 2024
Healthcare
$27.87
-0.02 (-1.71%)
Lowest Today
$27.62
Highest Today
$27.93
Today’s Open
$27.87
Prev. Close
$28.12
52 Week High
$42.46
52 Week Low
$24.16
To Invest in Galapagos NV

Galapagos NV

Healthcare
GLPG30 Nov 2024
-0.02 (-1.71%)
1M
3M
6M
1Y
5Y
Low
$27.62
Day’s Range
High
$27.93
27.62
52 Week Low
$24.16
52-Week Range
52 Week High
$42.46
24.16
1 Day
-
1 Week
+1.17%
1 month return
-3.08%
3 month return
-5.16%
6 month return
+0.87%
1 Year return
-26.22%
3 Years return
-43%
5 Years return
-85.87%
10 Years return
-
Institutional Holdings
FMR Inc
2.43
Bvf Inc
2.38
Deerfield Management Co
2.14
Prosight Management, LP
2.05
PRIMECAP Management Company
1.09
Segall Bryant & Hamill
1.07
TANG CAPITAL MANAGEMENT LLC
1.06

Market Status

Fundamentals
Market Cap
1853.03 mln
PB Ratio
0.62
PE Ratio
0
Enterprise Value
-1661.34 mln
Total Assets
4357.4 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Organisation
Galapagos NV
Employees
1123
Industry
Biotechnology
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities